Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review - Takeaways - MDSpire

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • By

  • Anna M. Dornisch

  • Allison Y. Zhong

  • Darren M. C. Poon

  • Alison C. Tree

  • Tyler M. Seibert

  • January 20, 2024

  • 0 min

Share

  • 1

    Focal radiotherapy boosts to MR-visible tumors in prostate cancer improve biochemical disease-free survival without increasing toxicity.

  • 2

    The FLAME trial demonstrated that adding a focal RT boost enhances treatment outcomes for localized intermediate and high-risk prostate cancer patients.

  • 3

    A meta-analysis showed a biochemical disease-free survival rate of 92.4% for patients receiving MR-guided focal boosts with over 5 years of follow-up.

  • 4

    The systematic review included 7 prospective phase II/III trials with a total of 723 patients undergoing MR-guided external beam radiotherapy.

  • 5

    Barriers to implementing MR-guided focal boosts were discussed, along with strategies to enhance clinical adoption of this treatment approach.

Original Source(s)

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • by Anna M. Dornisch, Allison Y. Zhong, Darren M. C. Poon, Alison C. Tree, Tyler M. Seibert

  • January 20, 2024

Related Content

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer